NDC product
Valsartan and Hydrochlorothiazide
NDC 51655-243 · Northwind Health Company, LLC
Key facts
| Product NDC | 51655-243 |
|---|---|
| Proprietary name | Valsartan and Hydrochlorothiazide |
| Nonproprietary name | valsartan and hydrochlorothiazide |
| Substances | VALSARTAN, HYDROCHLOROTHIAZIDE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Northwind Health Company, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA078020 |
| Pharmacologic classes | Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS] |
| Marketing start | Nov 16, 2022 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: